• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Novartis Ag ADR (NY: NVS )

    120.89 +0.47 (+0.39%)
    Official Closing Price Updated: 4:10 PM EDT, Aug 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 902,598
    Open 120.37
    Bid (Size) 119.00 (9)
    Ask (Size) 121.00 (3)
    Prev. Close 120.42
    Today's Range 120.06 - 120.92
    52wk Range 92.19 - 120.80
    Shares Outstanding N/A
    Dividend Yield 2.87%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Novartis' Cholesterol-Lowering Drug Shows Encouraging Outcome In Late-Stage Study
    Novartis announced positive Phase 3 V-MONO study results for Leqvio, showing significant LDL-C reduction in low and moderate ASCVD risk patients, as the company continues to explore its potential in... 
    Via Benzinga
    Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation
    From Lindy Biosciences
    Via Business Wire

    Performance

    YTD
    +19.69%
    +19.69%
    1 Month
    +8.01%
    +8.01%
    3 Month
    +20.05%
    +20.05%
    6 Month
    +19.73%
    +19.73%
    1 Year
    +18.62%
    +18.62%

    More News

    Read More
    Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats
    Via Investor's Business Daily
    Exposures Product Safety
    Siemens Healthineers To Buy Novartis Diagnostics To Bolster Cancer Scan Business In $220M Deal
    Via Benzinga
    Uncovering Dividend Opportunities with NYSE:NVS.
    Via Chartmill
    Good technical signals and a possible breakout for NOVARTIS AG-SPONSORED ADR.
    Via Chartmill
    Why NYSE:NVS is a Top Pick for Dividend Investors.
    Via Chartmill
    2 Unstoppable Healthcare Stocks to Buy Right Now With Less Than $200
    Via The Motley Fool
    Judge Rules Against Novartis' Effort To Halt Generic Launch Of Its Top-Selling Heart Disease Drug
    Via Benzinga
    The Cancer Battle - How Smaller Companies Are Making Big Advancements in Treatments for Solid Tumors
    Via Newsfile
    Exposures Product Safety
    BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model
    Via Investor Brand Network
    Novartis Reports Near 40% Margin In Q2; Shares Slide
    Via Investor's Business Daily
    FDA Approves Expanded Use Of Novartis' Rare Disease Drug Fabhalta For Kidney Disease
    Via Benzinga
    Exposures Product Safety
    Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs
    Via Benzinga
    Topics Lawsuit
    Exposures Financial Legal
    Alzheimer’s Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
    Via FinancialNewsMedia
    Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
    From FN Media Group LLC
    Via GlobeNewswire
    Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
    From Arvinas Inc.
    Via GlobeNewswire
    AstraZeneca, Sanofi And Other Pharma Giants Pursue Chinese Deals Despite Rising US-China Strife
    Via Benzinga
    Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
    Via Investor's Business Daily
    Pharma Leader Beats on Earnings, But Shares Fall
    Via MarketBeat
    Topics Intellectual Property
    Exposures Intellectual Property
    Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    Why Novartis Stock Is Down Today Despite Topping Q2 Estimates
    Via The Motley Fool
    VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday?
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Novartis' Q2 Earnings: Revenue And EPS Beat, Raises 2024 Profit Forecast On Strong Demand For Key Drugs
    Via Benzinga
    Wall Street Gearing Up For Tech-Led Rebound Ahead Of Netflix Earnings: Economist Expects Soft Landing But Says Brace For Bigger Fed Rate Cuts If This Happens
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.